Medicaid Provider Alert: Provider revalidation has begun and those not completing the process risk disenrollment. Check your account now to learn when your revalidation is due. More information here.

Drugs and Therapeutics (D & T) Committee Drugs Under Review for: September 14, 2016

Drugs and Therapeutics (D & T) Committee

Drug Name	Review Type	Class	Manufacturer
Viekira HR	New Drug Initial Review	Hepatitis C	AbbVie
Ocaliva	New Drug Initial Review	Primary Biliary Cholangitis	Intercept Pharmaceuticals
Briviact	New Drug Initial Review	Anticonvulsant	UCB, Inc.
Epclusa	New Drug Initial Review	Hepatitis C	Gilead Sciences
Xtampza ER	New Drug Initial Review	Extended Release Opioid	Collegium Pharmaceutical
Spinosad	New Drug Initial Review	Lice Treatment	ParaPro
Adzenys XR-ODT	New Drug Initial Review	Stimulant	Neos Therapeutics
Orenitram	New Drug Appeal	Pulmonary Arterial Hypertension	United Therapeutics